Table 2 Comparison of methylated HYP2 levels and MoM values between specific groups of patients and controls in the second and third trimesters.

From: Maternal total cell-free DNA in preeclampsia with and without intrauterine growth restriction

 

Controls

PE

GH

P†

Pa‡

Pb‡

Pc‡

2nd trimester

(n = 78)

(n = 29)

(n = 12)

    

Copies/mL

9,441

(5,878–12,251)

10,964

(6,770–17,509)

8,689

(6,584–11,968)

0.28

0.43

0.70

0.43

MoM

0.998

(0.952–1.026)

1.015

(0.962–1.062)

0.991

(0.946–1.015)

0.29

0.43

0.57

0.43

3rd trimester

(n = 58)

(n = 20)

(n = 7)

    

Copies/mL

14,969

(11,411–21,873)

59,488

(36,880–87,854)

28,265

(15,330–34,157)

 < .0001

 < .0001

0.11

0.013

MoM

0.979

(0.948–1.029)

1.090

(1.035–1.149)

0.986

(0.942–1.069)

 < .0001

 < .0001

0.53

0.032

  1. Data are given as median (interquartile range).
  2. Pa, PE versus controls; Pb, GH versus controls; Pc, PE versus GH.
  3. GH gestational hypertension, MoM multiple of the median, PE preeclampsia.
  4. †P value by the Kruskal–Wallis test.
  5. ‡P value by the Wilcoxon rank sum test (adjusted by the step-up Bonferroni method).
Back to article page